Effective treatment of established GL261 murine gliomas through picornavirus vaccination-enhanced tumor antigen-specific CD8+ T cell responses

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Renner, Danielle N ^a,b   Jin, Fang ^b   Litterman, Adam J ^c   Balgeman, Alexis J ^a   Hanson, Lisa M ^b   Gamez, Jeffrey D ^a   Chae, Michael ^a   Carlson, Brett L ^a   Sarkaria, Jann N ^a   Parney, Ian F ^a,b   Ohlfest, John R ^c   Pirko, Istvan ^a   Pavelko, Kevin D ^b   Johnson, Aaron J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PICORNAVIRUS VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS VACCINE; BIOLOGICAL MARKER; CANCER VACCINE; EPITOPE; OVA-8; OVALBUMIN; PEPTIDE FRAGMENT; PERFORIN, MOUSE; PORE FORMING CYTOTOXIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; GLIOMA; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; MOUSE; NONHUMAN; PICORNAVIRIDAE; TUMOR GROWTH; TUMOR VOLUME; VACCINATION; ANIMAL; BRAIN NEOPLASMS; C57BL MOUSE; CELL MOTION; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; MORTALITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELL LINE;

MURINAE; MUS; PICORNAVIRIDAE;

ANIMALS; ANTIGENS, NEOPLASM; BIOMARKERS; BRAIN NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION; GLIOMA; HUMANS; INJECTIONS, INTRAVENTRICULAR; MICE; MICE, INBRED C57BL; OVALBUMIN; PEPTIDE FRAGMENTS; PICORNAVIRIDAE; PORE FORMING CYTOTOXIC PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VACCINATION;

EID: 84928822533     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125565     Document Type: Article

References (51)

1. Stupp R, Hegi ME, Mason WP, Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology. 2009; 10(5). doi: 10.1016/S1470-2045(09)70025-7
2. Nieder C, Grosu AL, Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev. 2000; 26(6):397-409. Epub 2001/01/05. doi: 10.1053/ctrv.2000.0191 PMID: 11139371.
3. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011; 17(6):1603-15. Epub 2010/12/08. doi: 10.1158/1078-0432.CCR-10-2563 PMID: 21135147; PubMed Central PMCID: PMC3071163.
4. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother. 2011; 34(4):382- 9. Epub 2011/04/19. doi: 10.1097/CJI.0b013e318215e300 PMID: 21499132.
5. Breart B, Lemaître F, Celli S, Bousso P. Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest. 2008; 118(4). doi: 10.1172/JCI34388
6. Barcia C Jr., Gomez A, Gallego-Sanchez JM, Perez-Valles A, Castro MG, Lowenstein PR, et al. Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells. Am J Pathol. 2009; 175(2):786-98. Epub 2009/07/25. doi: 10.2353/ajpath.2009.081034 PMID: 19628762; PubMed Central PMCID: PMC2716973.
7. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008; 68(14):5955-64. Epub 2008/07/18. doi: 10.1158/0008-5472.CAN-07-5973 PMID: 18632651.
8. Yang J, Sanderson NS, Wawrowsky K, Puntel M, Castro MG, Lowenstein PR. Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo. Proc Natl Acad Sci U S A. 2010; 107(10):4716-21. Epub 2010/02/06. doi: 10.1073/pnas.0911587107 PMID: 20133734; PubMed Central PMCID: PMC2842057.
9. Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med. 2007; 204(2):1-12. doi: 10.1084/jem.20061890
10. Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother. 2007; 30(8):789-97. Epub 2007/12/01. doi: 10.1097/CJI.0b013e318155a0f6 PMID: 18049330.
11. Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, et al. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res. 2009; 15(21):6551-9. Epub 2009/10/29. doi: 10.1158/1078-0432.CCR-09-1067 PMID: 19861464; PubMed Central PMCID: PMC2783346.
12. Ausman JI, Shapiro WR, Rall DP. Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res. 1970; 30(9):2394-400. Epub 1970/09/01. PMID: 5475483.
13. Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother. 2011; 60(2):153-60. Epub 2010/12/02. doi: 10.1007/s00262-010-0946-6 PMID: 21120655.
14. Xiong Z, Ohlfest JR. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. J Immunother. 2011; 34(3):264-9. Epub 2011/03/11. doi: 10.1097/CJI.0b013e318209eed4 PMID: 21389872; PubMed Central PMCID: PMC3073686.
15. Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 2003; 63(23):8487-91. Epub 2003/12/18. PMID: 14679014.
16. Zagzag D, Amirnovin R, Greco MA, Yee H, Holash J, Wiegand SJ, et al. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest. 2000; 80(6):837-49. Epub 2000/07/06. PMID: 10879735.
17. Eyupoglu IY, Hahnen E, Heckel A, Siebzehnrubl FA, Buslei R, Fahlbusch R, et al. Malignant glioma-induced neuronal cell death in an organotypic glioma invasion model. Technical note. J Neurosurg. 2005; 102(4):738-44. Epub 2005/05/06. doi: 10.3171/jns.2005.102.4.0738 PMID: 15871520.
18. Ohlfest JR, Andersen BM, Litterman AJ, Xia J, Pennell CA, Swier LE, et al. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J Immunol. 2013; 190(2):613-20. Epub 2012/12/19. doi: 10.4049/jimmunol.1201557 PMID: 23248259; PubMed Central PMCID: PMC3538956.
19. Johnson AJ, Njenga MK, Hansen MJ, Kuhns ST, Chen L, Rodriguez M, et al. Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28. J Virol. 1999; 73(5):3702-8. Epub 1999/04/10. PMID: 10196262; PubMed Central PMCID: PMC104145.
20. Dethlefs S, Escriou N, Brahic M, van der Werf S, Larsson-Sciard EL. Theiler's virus and Mengo virus induce cross-reactive cytotoxic T lymphocytes restricted to the same immunodominant VP2 epitope in C57BL/6 mice. J Virol. 1997; 71(7):5361-5. Epub 1997/07/01. PMID: 9188606; PubMed Central PMCID: PMC191774.
21. Pavelko KD, Girtman MA, Mitsunaga Y, Mendez-Fernandez YV, Bell MP, Hansen MJ, et al. Theiler's murine encephalomyelitis virus as a vaccine candidate for immunotherapy. PLoS One. 2011; 6(5): e20217. Epub 2011/06/01. doi: 10.1371/journal.pone.0020217 PMID: 21625449; PubMed Central PMCID: PMC3098865.
22. Pavelko KD, Bell MP, Karyampudi L, Hansen MJ, Allen KS, Knutson KL, et al. The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine. Mol Ther. 2013; 21(5):1087-95. Epub 2013/04/10. doi: 10.1038/mt.2013.52 PMID: 23568262.
23. Johnson AJ, Upshaw J, Pavelko KD, Rodriguez M, Pease LR. Preservation of motor function by inhibition of CD8+ virus peptide-specific T cells in Theiler's virus infection. Faseb J. 2001; 15(14):2760-2. Epub 2001/10/19. doi: 10.1096/fj.01-0373fje PMID: 11606479.
24. Litterman AJ, Zellmer DM, Grinnen KL, Hunt MA, Dudek AZ, Salazar AM, et al. Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol. 2013; 190(12):6259-68. Epub 2013/05/21. doi: 10.4049/jimmunol.1203539 PMID: 23686484; PubMed Central PMCID: PMC3680135.
25. Johnson HL, Chen Y, Jin F, Hanson LM, Gamez JD, Pirko I, et al. CD8 T cell-initiated blood-brain barrier disruption is independent of neutrophil support. J Immunol. 2012; 189(4):1937-45. Epub 2012/07/10. doi: 10.4049/jimmunol.1200658 PMID: 22772449; PubMed Central PMCID: PMC3411871.
26. Pirko I, Suidan GL, Rodriguez M, Johnson AJ. Acute hemorrhagic demyelination in a murine model of multiple sclerosis. J Neuroinflammation. 2008; 5:31. Epub 2008/07/09. doi: 10.1186/1742-2094-5-31 PMID: 18606015; PubMed Central PMCID: PMC2474604.
27. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996; 274(5284):94-6. Epub 1996/10/04. PMID: 8810254.
28. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. Epub 2008/06/13. PMID: 18546601.
29. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987; 66(6):865-74. Epub 1987/06/01. doi: 10.3171/jns.1987.66.6.0865 PMID: 3033172.
30. Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of 18FDOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol. 2013; 15(8):1058-67. Epub 2013/03/06. doi: 10.1093/neuonc/not002 PMID: 23460322; PubMed Central PMCID: PMC3714146.
31. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162-74. Epub 2009/02/07. doi: 10.1038/nri2506 PMID: 19197294; PubMed Central PMCID: PMC2828349.
32. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol. 2008; 83(5):1136-44. Epub 2008/02/21. doi: 10.1189/jlb.0907611 PMID: 18285406.
33. Iwama T, Yamada H, Sakai N, Andoh T, Nakashima T, Hirata T, et al. Correlation between magnetic resonance imaging and histopathology of intracranial glioma. Neurol Res. 1991; 13(1):48-54. Epub 1991/03/01. PMID: 1675447.
34. Chen XZ, Yin XM, Ai L, Chen Q, Li SW, Dai JP. Differentiation between brain glioblastoma multiforme and solitary metastasis: qualitative and quantitative analysis based on routine MR imaging. AJNR American journal of neuroradiology. 2012; 33(10). doi: 10.3174/ajnr.A3106
35. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996; 27(1). PMID: 8699230
36. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007; 25(16):2295-305. Epub 2007/06/01. doi: 10.1200/JCO.2006.09.9861 PMID: 17538176.
37. Parney IF, Waldron JS, Parsa AT. Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg. 2009; 110(3):572-82. Epub 2009/02/10. doi: 10.3171/2008.7.JNS08475 PMID: 19199469; PubMed Central PMCID: PMC3064468.
38. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010; 12(11):1113-25. Epub 2010/07/30. doi: 10.1093/neuonc/noq082 PMID: 20667896; PubMed Central PMCID: PMC3098021.
39. Dziurzynski K, Wei J, Qiao W, Hatiboglu MA, Kong LY, Wu A, et al. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. 2011; 17(14):4642-9. Epub 2011/04/15. doi: 10.1158/1078-0432.CCR-11-0414 PMID: 21490182; PubMed Central PMCID: PMC3139801.
40. Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol. 2010; 12(4):351-65. Epub 2010/03/24. doi: 10.1093/neuonc/nop023 PMID: 20308313; PubMed Central PMCID: PMC2940603.
41. Cantini G, Pisati F, Mastropietro A, Frattini V, Iwakura Y, Finocchiaro G, et al. A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Cancer Immunol Immunother. 2011; 60(12):1739-50. Epub 2011/07/23. doi: 10.1007/s00262-011-1069-4 PMID: 21779877.
42. El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg. 2006; 105(3):430-7. Epub 2006/09/12. doi: 10.3171/jns.2006.105.3.430 PMID: 16961139.
43. Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, et al. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol. 2009; 11(5):529-42. Epub 2009/04/02. doi: 10.1215/15228517-2009-004 PMID: 19336528; PubMed Central PMCID: PMC2765342.
44. Learn CA, Fecci PE, Schmittling RJ, Xie W, Karikari I, Mitchell DA, et al. Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res. 2006; 12(24):7306-15. Epub 2006/12/26. doi: 10.1158/1078-0432.CCR-06-1727 PMID: 17189402.
45. Iizuka Y, Kojima H, Kobata T, Kawase T, Kawakami Y, Toda M. Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine. Int J Cancer. 2006; 118 (4):942-9. Epub 2005/09/10. doi: 10.1002/ijc.21432 PMID: 16152596.
46. Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, et al. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med. 2004; 2(1):40. Epub 2004/11/26. doi: 10.1186/1479-5876-2-40 PMID: 15563374; PubMed Central PMCID: PMC535538.
47. Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S, et al. TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol. 2008; 181(10):6720-9. Epub 2008/11/05. PMID: 18981089.
48. Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst. 2007; 99(21):1623-33. Epub 2007/11/01. doi: 10.1093/jnci/djm198 PMID: 17971529.
49. Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, et al. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010; 55(2):295-303. Epub 2010/06/29. doi: 10.1002/pbc.22535 PMID: 20582972; PubMed Central PMCID: PMC3003870.
50. Zoll J, Erkens Hulshof S, Lanke K, Verduyn Lunel F, Melchers WJ, Schoondermark-van de Ven E, et al. Saffold virus, a human Theiler's-like cardiovirus, is ubiquitous and causes infection early in life. PLoS Pathog. 2009; 5(5):e1000416. Epub 2009/05/05. doi: 10.1371/journal.ppat.1000416 PMID: 19412527; PubMed Central PMCID: PMC2670511.
51. Rudin CM, Poirier JT, Senzer NN, Stephenson J, Loesch D, Burroughs KD, et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res. 2011; 17(4). doi: 10.1158/1078-0432.CCR-10-1706